Onconetix, INC 8-K filings

Onconetix, Inc. received a notice from Nasdaq for failing to file its quarterly report on time, but has since filed the report.

Onconetix, Inc. has amended its forbearance agreement with Veru Inc., delaying a payment and increasing the percentage of future transaction proceeds owed to Veru.

Onconetix Inc. reports the resignation of its independent auditor, EisnerAmper LLP, effective after the filing of the September 30, 2024 quarterly report, citing no disagreements but noting previously disclosed material weaknesses in internal controls.

Onconetix, Inc. successfully addressed Nasdaq listing deficiencies through a reverse stock split and the issuance of new shares, regaining compliance with minimum bid price and stockholders' equity requirements.

Onconetix, a cancer diagnostics company, has finalized a $2 million private placement and established a $25 million equity line of credit to fund operations and growth.

Onconetix, Inc. issued warrants to Altos Venture AG, completed a 1-for-40 reverse stock split, and regained compliance with Nasdaq listing requirements.

Onconetix has amended its forbearance agreement with Veru, extending the maturity date of a $5 million note to June 30, 2025, and modifying payment terms on existing debt.

Onconetix has announced a 1-for-40 reverse stock split effective September 24, 2024, and the approval of all proposals at its 2024 annual meeting, including an increase in shares available under its equity incentive plan.

Onconetix, Inc. announces the approval of all proposals at its 2024 annual meeting, including director elections, an increase in share authorization, a reverse stock split, and various share issuances.

Onconetix, Inc. has released pro forma financial statements reflecting the acquisition of Proteomedix and a pending conversion of preferred stock, as it seeks a Nasdaq listing.

Onconetix is seeking shareholder approval for a reverse stock split to regain compliance with Nasdaq listing requirements after receiving notices regarding minimum bid price and stockholders' equity.

Onconetix has announced deadlines for shareholder proposals and director nominations for its upcoming 2024 annual meeting.

Onconetix has closed a warrant exercise, generating $1.11 million in gross proceeds and issuing new warrants for future share purchases.

Onconetix, Inc. has entered into agreements for the exercise of existing warrants, resulting in new investment options and expected gross proceeds of approximately $1.11 million.

Onconetix Inc. has appointed Karina Fedasz as Interim Chief Financial Officer, outlining a consulting agreement with a monthly fee and additional compensation for signatory services.

Onconetix, Inc. announces the resignation of its Chief Financial Officer, Bruce Harmon, and the appointment of Karina M. Fedasz as Interim CFO, along with a severance agreement for Harmon.

Onconetix, Inc. received a notice from Nasdaq for not meeting the minimum stockholders' equity requirement for continued listing.

Onconetix, Inc. has entered into a forbearance agreement with Veru Inc. and amended a debenture with Altos Ventures, while also pausing commercialization of ENTADFI and reducing staff.

Onconetix, Inc. has been granted an additional 180-day extension by Nasdaq to regain compliance with the minimum bid price requirement, extending the deadline to September 16, 2024.

Onconetix has filed an amendment to its previous 8-K report to include the consent of Proteomedix's auditor, BDO AG, for incorporation of their audit report into Onconetix's registration statements.

Onconetix, Inc. has finalized its acquisition of Proteomedix AG, filing an amended 8-K to include the acquired company's financial statements and pro forma information.

Onconetix has appointed Dr. Ajit Singh and Dr. Thomas Meier to its Board of Directors, bringing extensive biotech and commercial experience.

Onconetix, Inc. has appointed Thomas Meier, PhD, to its board of directors, effective February 6, 2024, as part of an agreement with Series B Convertible Preferred Stock holders.

Onconetix, Inc. has issued a $5 million non-convertible debenture to an investor, with repayment tied to a subscription agreement or a June 30, 2024 maturity date.

Onconetix, Inc. has entered into a separation agreement with its former Chief Business Officer, Erin Henderson, and engaged her consulting firm, The Aetos Group, for a three-month period.

Onconetix, Inc. announces the resignation of its CEO, Dr. Neil Campbell, and the appointment of an interim CEO, Dr. Ralph Schiess, along with James Sapirstein as Lead Independent Director.